New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
10:46 EDTHLF, EJ, EDU, TSEM, GALT, KS, BCOR, AXL, PII, SBACHigh option volume stocks: SBAC KS EDU PII GALT EJ AXL TSEM HLF BCOR
News For SBAC;KS;EDU;PII;GALT;EJ;AXL;TSEM;HLF;BCOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 19, 2015
10:23 EDTPIIHigh option volume stocks
Subscribe for More Information
10:15 EDTTSEMTower Semiconductor management to meet with Craig Hallum
Subscribe for More Information
07:21 EDTEJE-House price target lowered to $13 from $16 at Brean Capital
Subscribe for More Information
05:48 EDTAXLAmerican Axle price target raised to $30 from $25 at Barclays
Subscribe for More Information
March 18, 2015
17:14 EDTGALTGalectin submitted request for SPA with clinical protocol for GR-MD-02 trial
"I am pleased with our many accomplishments during 2014 as we continue to advance programs with GR-MD-02 for the treatment of nonalcoholic steatohepatitis, NASH, with advanced fibrosis. We completed a successful Phase 1 clinical trial and announced final data in January 2015 that were supportive of our plans to begin a Phase 2 program with GR-MD-02 in advanced fatty liver disease, or NASH with fibrosis and cirrhosis," said Peter G. Traber, M.D., president, CEO and chief medical officer of Galectin Therapeutics. "As announced last month, we submitted the Phase 2 clinical trial protocol to the U.S. Food and Drug Administration, FDA, to evaluate the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis, the primary endpoint being to determine the change in the hepatic venous pressure gradient, HVPG, as compared with placebo. The FDA has indicated that HVPG may serve as a surrogate primary endpoint for NASH cirrhosis. We submitted a request for a Special Protocol Assessment with the clinical protocol for this trial. Additionally, we are planning to conduct a separate, shorter Phase 2 trial in NASH patients with advanced fibrosis. We expect to begin enrolling patients in both trials during the second quarter of 2015."
17:08 EDTGALTGalectin Therapeutics reports FY14 EPS (78c), consensus (77c)
As of December 31, the company had $29.1M of non-restricted cash and cash equivalents available to fund future operations. In January and February of 2015, the company received $4.1M in net proceeds from the issuance of common shares through its At-the-Market stock issuance program. The company believes that cash on hand of $29.7M as of March 13, is sufficient to fund its operations and research and development activities through September 30, 2016.
15:21 EDTPIIPolaris Industries has a conference call hosted by UBS
UBS will host a conference call with CFO Mike Malone and Richard Edwards, Investor Relations on March 20 at 10:30 am.
13:49 EDTHLFHerbalife says 'confident in strong fundamentals of business model'
Subscribe for More Information
09:23 EDTHLFOn The Fly: Pre-market Movers
Subscribe for More Information
08:02 EDTHLFHerbalife wins dismissal of class action 'pyramid scheme' lawsuit
On March 16, a judge in the U.S. District Court for the Central District of California granted Herbalife its motion to dismiss a class action complaint brought on behalf of shareholders who allege that the company and its executives violated federal securities laws by misrepresenting the "nature, scope and legality" of the company's business and operations. According to the plaintiffs, Herbalife and its executives, including CEO Michael Johnson, misrepresented Herbalife as a legitimate multi-level marketing company when it "is actually an illegal pyramid scheme." The court concluded that the suit's plaintiffs have not adequately pled loss causation, meaning that the court need not consider Herbalife’s alternative arguments, according to a court filing. Shares of Herbalife are up 3% in pre-market trading after the court dismissal was widely reported by Bloomberg last night.
07:13 EDTHLFHerbalife complaint letter signer subpoenaed, Hartford Courant reports
Subscribe for More Information
06:40 EDTEJE-House sees FY15 revenue $1.05B-$1.1B, consensus $1.05B
Subscribe for More Information
06:39 EDTEJE-House reports Q4 EPS 14c, consensus 19c
Reports Q4 revenue $312.3M, consensus $281.01M.
March 17, 2015
19:42 EDTHLFOn The Fly: After Hours Movers
Subscribe for More Information
18:27 EDTHLFHerbalife up over 5% following favorable court ruling in 'pyramid scheme' suit
Subscribe for More Information
18:07 EDTHLFHerbalife wins dismissal of 'pyramid scheme' lawsuit, Bloomberg says
15:18 EDTEJNotable companies reporting before tomorrow's open
Subscribe for More Information
10:26 EDTHLFOptions with increasing implied volatility
Subscribe for More Information
March 16, 2015
17:13 EDTGALTGalectin Therapeutics files form to delay 10-K
Galectin Therapeutics is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the period ended December 31. Because the company was previously a smaller reporting company, this is the first time the company must obtain an audit of its internal control over financial reporting. As a result, additional time is needed for the company to provide its independent auditors with information necessary to complete the audit of the company’s internal control over financial reporting. The company anticipates that its Form 10-K will be filed within the prescribed extension period in accordance with Rule 12b-25(b).
05:50 EDTHLFStocks with implied volatility movement; FIG HLF
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use